3rd Party Biotechnology Industry News

Biogen has discontinued all gene therapy programs using adeno-associated virus [...]

Together, the two programs represent a nine-figure investment from the [...]

While Eli Lilly is rethinking its biotech incubator plans in [...]

U.S. biotechs are increasingly reluctant to license their drugs to [...]

Belén Garijo, who steered the German healthcare and electronics conglomerate [...]

The National Institutes of Health is continuing its mission to [...]

Eli Lilly has pulled the plug on a phase 2b [...]

The FDA’s rejection of Telix Pharmaceuticals’ imaging agent has triggered [...]

Merck & Co. is choosing to license one of Evaxion’s [...]

While the average earnout potential per biopharma deal has declined [...]